• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Sweat chloride levels predict future cystic fibrosis diagnosis in those with inconclusive diagnosis at birth

byMolly MunsellandAlex Gipsman, MD
November 17, 2021
in Chronic Disease, Pediatrics, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In a prospective multi-center study, 21% of children with cystic fibrosis screen positive, inconclusive diagnosis (CFSPID) at birth were later reclassified to a diagnosis of cystic fibrosis (CF).

2. Initial sweat chloride value on the high end of normal predicted eventual diagnosis of CF.

Evidence Rating Level: 2 (Good)

Study Rundown: Screening for cystic fibrosis (CF) has been part of routine newborn care for decades in the United States and Canada. After a positive screening for elevated immunoreactive trypsinogen, the diagnosis of CF is typically made based on genetic testing for disease-causing variants of the CFTR gene as well as elevated sweat chloride. Infants with cystic fibrosis screen positive, inconclusive diagnosis (CFSPID) have either 2 CFTR gene variants, at least 1 of which is not known to be CF-causing, or borderline sweat chloride values of 30 to 59 mmol/L. This ongoing, longitudinal, multi-center study examined long-term outcomes for children across Canada falling into this diagnostic gray area. These children were compared to controls with diagnosed CF, with and without pancreatic insufficiency. At a mean follow-up time of 7.7 years, 21% of 115 children with CFSPID were eventually diagnosed with CF based on either reinterpretation of gene variants or increased sweat chloride. Children with CFSPID had normal heights and weights at age 6, and normal lung function. Children with CFSPID and initial sweat chloride 40 mmol/L or greater were more likely to eventually be diagnosed with CF. This study’s limitations include its relatively small sample size and the timing of this interim analysis, as differences in growth, pulmonary function, and pancreatic function due to CF may not manifest until early adulthood. However, this study presents compelling evidence supporting the use of sweat chloride as a biomarker to predict a future diagnosis of CF in children with CFSPID.

Click to read the study in Pediatrics

Relevant Reading: Cystic fibrosis screen positive, inconclusive diagnosis (CFSPID): A new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening

In-Depth [prospective cohort]: The CFTR2 database was used to determine whether individual CFTR gene variants were pathogenic. 27% of the original cohort with CFSPID was lost to follow-up. Linear regression models were used for analysis of anthropometric and pulmonary function measures. Pulmonary function was assessed using both FEV1 and lung clearance index (LCI). FEV1 was not significantly different between CFSPID and CF. LCI was lower in CFSPID than in CF patients. Respiratory bacteria were also sampled, and were overall similar between CFSPID and CF patients though with low frequency of positive cultures in both groups. A proportional hazards model was used to analyze sweat chloride as a possible predictor of CF diagnosis. The hazard ratio for conversion to CF in CFSPID patients with initial sweat chloride 40 or greater compared to <40 mmol/L was 12.1 (95% confidence interval 2.6-55.6). Immunoreactive trypsinogen screening values did not predict later CF diagnosis in a similar analysis.

RELATED REPORTS

Higher body mass index associated with improved cystic fibrosis-related clinical outcomes

#VisualAbstract: Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

In utero administration of ivacaftor averts multiorgan disease in ferret model of cystic fibrosis [PreClinical]

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cystic fibrosisnewborn screeningsweat test
Previous Post

Association of self-reported COVID-19 infection and SARS-CoV-2 serology results with persistent physical symptoms

Next Post

#VisualAbstract: Head and neck cancers are highly prevalent among alcohol consumption-associated malignancies in the global population

RelatedReports

Improved glycemic control in type 1 diabetics on very low-carbohydrate diets
Chronic Disease

Higher body mass index associated with improved cystic fibrosis-related clinical outcomes

March 7, 2022
#VisualAbstract: Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
StudyGraphics

#VisualAbstract: Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

November 28, 2019
In utero administration of ivacaftor averts multiorgan disease in ferret model of cystic fibrosis [PreClinical]
Chronic Disease

In utero administration of ivacaftor averts multiorgan disease in ferret model of cystic fibrosis [PreClinical]

April 4, 2019
Weekly Rewinds

2 Minute Medicine Rewind December 4, 2017

December 16, 2017
Next Post
#VisualAbstract: High-dose glucocorticoids may be detrimental for the management of patients with advanced melanoma expieriencing immune-related adverse events

#VisualAbstract: Head and neck cancers are highly prevalent among alcohol consumption-associated malignancies in the global population

Sacubitril or valsartan versus standard medical therapies in patients with heart failure with preserved ejection fraction: PARALLAX trial

Adolescents’ muscle strength associated with lower cardiometabolic risk

Wellness Check: Exercise

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sickle cell trait associated with preexisting kidney comorbidities and increased COVID-19 mortality
  • Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
  • FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.